Equities

Shanghai Shen Lian Biomedical Corp

688098:SHH

Shanghai Shen Lian Biomedical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.24
  • Today's Change-0.28 / -5.07%
  • Shares traded3.28m
  • 1 Year change-34.09%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments207358468
Total Receivables, Net277230161
Total Inventory112115103
Prepaid expenses2.092.741.14
Other current assets, total0.13----
Total current assets598706733
Property, plant & equipment, net823777769
Goodwill, net------
Intangibles, net1369568
Long term investments1.591.581.57
Note receivable - long term------
Other long term assets------
Total assets1,5941,6051,598
LIABILITIES
Accounts payable5.148.8611
Accrued expenses202627
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.330.140.13
Other current liabilities, total516275
Total current liabilities7797114
Total long term debt0.920.310.38
Total debt1.250.450.51
Deferred income tax0.020.390.27
Minority interest180(5.89)
Other liabilities, total9.491011
Total liabilities105108120
SHAREHOLDERS EQUITY
Common stock411411411
Additional paid-in capital539546552
Retained earnings (accumulated deficit)539540516
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,4891,4971,479
Total liabilities & shareholders' equity1,5941,6051,598
Total common shares outstanding411411411
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.